saplin

quant Healthcare Fund

quant Healthcare Fund (Direct, Growth): saplin Score 7.6/10 (Neutral) among 126 Sectoral/Thematic funds. 3Y return 21.6% a year vs 14.7% category median, expense ratio 1.57%. Returns that beat most peers, but higher costs than most peers. NAV ₹19.50 on 11 Nov 2026.

Loading the full analysis…

Questions about quant Healthcare Fund

What is the expense ratio of quant Healthcare Fund?

The Direct plan's total expense ratio is 1.57% a year, against a median of 1.20% for sectoral/thematic funds. The Regular plan costs more because it pays a distributor's commission.

What are the top holdings of quant Healthcare Fund?

Zydus Lifesciences 10.25%, Divi's Laboratories 9.92%, Aurobindo Pharma 9.83%, Glenmark Pharmaceuticals 9.38%, Glaxosmithkline Pharmaceuticals 8.89% of the portfolio, as of 30 Oct 2026.

What returns has quant Healthcare Fund given?

1 year: 22.6% (category median 4.6%); 3 years: 21.6% a year (category median 14.7%). Past returns do not predict future ones.

How big is quant Healthcare Fund?

About ₹412 cr (AMFI's average for the latest quarter).

How does quant Healthcare Fund score?

7.6 out of 10 (Neutral) on the saplin Score, which rates a fund against its own category on returns, risk, consistency, cost and its manager. See the methodology for how it is worked out.

More on quant Healthcare